AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31185917 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anaesthesia and analgesia (EGA group, n = 20)
Number of subjects: 40
Study 31185917 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia (GA group, n = 20)
Number of subjects: 40
Study 31185917 — intervention group
Group type: EXPERIMENTAL
Intervention: EGA group
Number of subjects: 40
Study 31185917 — intervention group
Group type: COMPARATOR
Intervention: GA group
Number of subjects: 40
Study 31185917 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 27657979 — intervention group
Group type: EXPERIMENTAL
Intervention: Vets Prevail program
Number of subjects: 303
Study 27657979 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 303
Study 25209545 — intervention group
Group type: EXPERIMENTAL
Intervention: In-feed ZnO at 3000 mg/kg
Number of subjects: 110
Study 25209545 — intervention group
Group type: COMPARATOR
Intervention: Control feed with 100 mg ZnO/kg
Number of subjects: 110
Study 25046055 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitiglinide 10 mg and voglibose 0.2 mg (three-times-daily before each meal)
Number of subjects: 12
Study 25046055 — intervention group
Group type: COMPARATOR
Intervention: Mitiglinide 10 mg and voglibose 0.2 mg (twice-daily before breakfast and dinner)
Number of subjects: 12
Study 25046055 — intervention group
Group type: COMPARATOR
Intervention: DPP-4 inhibitor
Number of subjects: 12
Study 22119455 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol maintenance and reliever therapy (Symbicort SMART) at 2 × 2 (160/4.5 μg)
Number of subjects: 8424
Study 22119455 — intervention group
Group type: COMPARATOR
Intervention: Budesonide/formoterol maintenance and reliever therapy (Symbicort SMART) at 1 × 2 (160/4.5 μg)
Number of subjects: 8424
Study 19885422 — intervention group
Group type: EXPERIMENTAL
Intervention: 16% carbamide peroxide (bleached)
Number of subjects: 60
Study 19885422 — intervention group
Group type: COMPARATOR
Intervention: Control group (no bleaching)
Number of subjects: 60
Study 17804386 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-limited, trauma-focused group intervention
Number of subjects: 5
Study 17804386 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 5
Study 14716472 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg, single oral dose)
Number of subjects: 32
Study 14716472 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 11554699 — intervention group
Group type: EXPERIMENTAL
Intervention: Efficacy testing of cosmetic products
Number of subjects: 0
Study 11554699 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 10024837 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous quinaprilat (2.5, 5, or 10 mg BID)
Number of subjects: 55
Study 10024837 — intervention group
Group type: COMPARATOR
Intervention: Oral quinapril (10, 20, or 40 mg OD)
Number of subjects: 55
Study 10024837 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous quinaprilat
Number of subjects: 55
Study 10024837 — intervention group
Group type: COMPARATOR
Intervention: Oral quinapril
Number of subjects: 55
Study 7907012 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold compressive Cryocuff dressing
Number of subjects: 76
Study 7907012 — intervention group
Group type: COMPARATOR
Intervention: ACE wrap and ice pack (Control)
Number of subjects: 76
Study 2240002 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 0
Study 2240002 — intervention group
Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 0
Study 752875 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant BCG immunotherapy (intradermal and oral BCG)
Number of subjects: 107
Study 752875 — intervention group
Group type: COMPARATOR
Intervention: Control group (no BCG immunotherapy)
Number of subjects: 107
Study 31557064 — intervention group
Group type: COMPARATOR
Intervention: Fluorouracil plus radiotherapy
Number of subjects: 495
Study 31557064 — intervention group
Group type: EXPERIMENTAL
Intervention: mFOLFOX6 plus radiotherapy
Number of subjects: 495
Study 31557064 — intervention group
Group type: EXPERIMENTAL
Intervention: mFOLFOX6
Number of subjects: 495
Study 28494753 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving based intervention
Number of subjects: 0
Study 28494753 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 0
Study 25540929 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon occlusion hepatic venography
Number of subjects: 58
Study 25540929 — intervention group
Group type: COMPARATOR
Intervention: Wedged hepatic venography
Number of subjects: 58
Study 24045604 — intervention group
Group type: EXPERIMENTAL
Intervention: Onabotulinum toxin A (BTX)
Number of subjects: 36
Study 24045604 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 21774288 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl-propofol group (1 mcg/kg fentanyl)
Number of subjects: 40
Study 21774288 — intervention group
Group type: COMPARATOR
Intervention: Saline-propofol group (control group)
Number of subjects: 40
Study 19628410 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 2485
Study 16728216 — intervention group
Group type: EXPERIMENTAL
Intervention: High blood glucose levels (quartile 4)
Number of subjects: 9020
Study 16728216 — intervention group
Group type: COMPARATOR
Intervention: Low blood glucose levels (quartile 1)
Number of subjects: 9020
Study 16728216 — intervention group
Group type: EXPERIMENTAL
Intervention: High blood glucose levels (quartile 4) after multivariable adjustment
Number of subjects: 9020
Study 16728216 — intervention group
Group type: EXPERIMENTAL
Intervention: B-type natriuretic peptide levels
Number of subjects: 9020
Study 16728216 — intervention group
Group type: EXPERIMENTAL
Intervention: Troponin I levels
Number of subjects: 9020
Study 15175887 — intervention group
Group type: COMPARATOR
Intervention: Closed reduction and immobilisation with a short‐arm cast for 4 weeks (Group A)
Number of subjects: 50
Study 15175887 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsal block splinting of the PIP joint with daily active exercise (Group B)
Number of subjects: 50
Study 11775046 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine (immediate release, N = 474; extended release, N = 377)
Number of subjects: 2045
Study 11775046 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective Serotonin Reuptake Inhibitors (SSRIs, N = 748)
Number of subjects: 2045
Study 11775046 — intervention group
Group type: COMPARATOR
Intervention: Placebo (N = 446)
Number of subjects: 2045
Study 11775046 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 2045
Study 11775046 — intervention group
Group type: EXPERIMENTAL
Intervention: SSRIs
Number of subjects: 2045
Study 9863097 — intervention group
Group type: EXPERIMENTAL
Intervention: Theo-polyphenols (TP) treatment
Number of subjects: 38
Study 7934599 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical bovine collagen applied weekly to the wound
Number of subjects: 111
Study 7934599 — intervention group
Group type: COMPARATOR
Intervention: No collagen applied to the wound (control group)
Number of subjects: 111
Study 3391871 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin acistrate (EA) 400 mg tid
Number of subjects: 42
Study 3391871 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin stearate (ES) 500 mg tid
Number of subjects: 42
Study 31915208 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined use of contact aspiration (CA) and stent retriever (SR)
Number of subjects: 0
Study 31915208 — intervention group
Group type: COMPARATOR
Intervention: Stent retriever (SR) alone
Number of subjects: 0
Study 31177243 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill walking
Number of subjects: 15
Study 31177243 — intervention group
Group type: COMPARATOR
Intervention: Overground walking
Number of subjects: 15
Study 27921320 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiselimod 0.4 mg
Number of subjects: 81
Study 27921320 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiselimod 0.8 mg
Number of subjects: 81
Study 27921320 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod 0.5 mg
Number of subjects: 81
Study 27921320 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 25195813 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple antiplatelet therapy (TAT, DAT plus cilostazol)
Number of subjects: 227
Study 25195813 — intervention group
Group type: COMPARATOR
Intervention: Dual antiplatelet therapy (DAT, aspirin and clopidogrel)
Number of subjects: 227
Study 23449607 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg for 26 weeks
Number of subjects: 50
Study 23449607 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 26 weeks
Number of subjects: 50
Study 21814477 — intervention group
Group type: COMPARATOR
Intervention: Control (Group A): Intralipid(®) 2 ml as a placebo 15 min before the cervical plexus block and at the end of the surgery
Number of subjects: 90
Study 21814477 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine analgesia (Group B): Placebo 15 min before the cervical plexus block and flurbiprofen 50 mg at the end of the surgery
Number of subjects: 90
Study 21814477 — intervention group
Group type: EXPERIMENTAL
Intervention: Preemptive analgesia (Group C): Intravenous flurbiprofen 50 mg 15 min before the cervical plexus block and a placebo at the end of the surgery
Number of subjects: 90
Study 18787838 — intervention group
Group type: EXPERIMENTAL
Intervention: Relevant object (green or red color)
Number of subjects: 0
Study 18787838 — intervention group
Group type: COMPARATOR
Intervention: Irrelevant object (gray or white color)
Number of subjects: 0
Study 17043939 — intervention group
Group type: COMPARATOR
Intervention: 10 mmHg CO(2) pneumoperitoneum (Group B)
Number of subjects: 109
Study 17043939 — intervention group
Group type: COMPARATOR
Intervention: 10 mmHg CO(2) pneumoperitoneum + intraperitoneal normal saline infusion (Group C)
Number of subjects: 109
Study 17043939 — intervention group
Group type: EXPERIMENTAL
Intervention: 14 mmHg CO(2) pneumoperitoneum (Group A)
Number of subjects: 109
Study 15853118 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA enriched foods (2 g fish oils)
Number of subjects: 213
Study 15853118 — intervention group
Group type: EXPERIMENTAL
Intervention: Soya-protein (25 g)
Number of subjects: 213
Study 15853118 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 213
Study 10640980 — intervention group
Group type: EXPERIMENTAL
Intervention: GM‐CSF (5 microg/kg subcutaneously)
Number of subjects: 56
Study 10640980 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 9302547 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Number of subjects: 60
Study 9302547 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 9302547 — intervention group
Group type: COMPARATOR
Intervention: Sober
Number of subjects: 60
Study 8328892 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate resistance exercise program (12-week, 3 days per week, submaximal regimen using ankle and wrist weights and hand grip exerciser)
Number of subjects: 27
Study 8328892 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 27
Study 3475553 — intervention group
Group type: EXPERIMENTAL
Intervention: Definitive diagnosis of food allergy and initiation of an appropriate elimination diet
Number of subjects: 132
Study 3475553 — intervention group
Group type: COMPARATOR
Intervention: Double-blind placebo-controlled oral food challenges
Number of subjects: 132
Study 30051441 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-hand four-needle suture with sled-shaped needle three-tail fixed stitch
Number of subjects: 156
Study 30051441 — intervention group
Group type: COMPARATOR
Intervention: Traditional tacking group
Number of subjects: 156
Study 26883689 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 IU vagitocin (oxytocin containing gel)
Number of subjects: 68
Study 26883689 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 68
Study 24998009 — intervention group
Group type: EXPERIMENTAL
Intervention: Pump treatment
Number of subjects: 331
Study 24998009 — intervention group
Group type: COMPARATOR
Intervention: Multiple daily injections
Number of subjects: 331
Study 22904246 — intervention group
Group type: EXPERIMENTAL
Intervention: OMT (Osteopathic Manipulative Treatment)
Number of subjects: 21
Study 22904246 — intervention group
Group type: EXPERIMENTAL
Intervention: LT (Light Touch)
Number of subjects: 21
Study 22904246 — intervention group
Group type: COMPARATOR
Intervention: TAU (Treatment as Usual)
Number of subjects: 21
Study 20575278 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced traffic during the Olympic Games leading to lower O3 concentrations (approximately 30% lower)
Number of subjects: 0
Study 20575278 — intervention group
Group type: EXPERIMENTAL
Intervention: O3 concentrations during the Olympic Games
Number of subjects: 0
Study 20575278 — intervention group
Group type: EXPERIMENTAL
Intervention: Meteorologic conditions during the Olympic Games
Number of subjects: 0
Study 20575278 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention strategy of reduced traffic
Number of subjects: 0
Study 18631000 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive video‐assisted thyroidectomy (MIVAT)
Number of subjects: 0
Study 18631000 — intervention group
Group type: COMPARATOR
Intervention: Open thyroidectomy
Number of subjects: 0
Study 15598943 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel-cisplatin (DC)
Number of subjects: 233
Study 15598943 — intervention group
Group type: COMPARATOR
Intervention: Vinorelbine-cisplatin (VC)
Number of subjects: 233
Study 15598943 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (A1)
Number of subjects: 233
Study 15598943 — intervention group
Group type: COMPARATOR
Intervention: Vinorelbine (B1)
Number of subjects: 233
Study 15598943 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (B2)
Number of subjects: 233
Study 15598943 — intervention group
Group type: COMPARATOR
Intervention: Vinorelbine (A2)
Number of subjects: 233
Study 12601105 — intervention group
Group type: EXPERIMENTAL
Intervention: IFNbeta treatment (Avonex, Betaferon, Rebif-22)
Number of subjects: 191
Study 12601105 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent NAb+ (neutralizing antibodies positive)
Number of subjects: 191
Study 12601105 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated NAb+
Number of subjects: 191
Study 12601105 — intervention group
Group type: EXPERIMENTAL
Intervention: NAb- (neutralizing antibodies negative)
Number of subjects: 191
Study 10367554 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg
Number of subjects: 16
Study 10367554 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone 7.5 mg
Number of subjects: 16
Study 10367554 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam 1 mg
Number of subjects: 16
Study 10367554 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 8909451 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilute tropicamide eye drops
Number of subjects: 14
Study 8909451 — intervention group
Group type: COMPARATOR
Intervention: Healthy age-matched control subjects
Number of subjects: 14
Study 1854617 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher serum concentration and area under the plasma concentration curve (AUC) of methotrexate (Mtx)
Number of subjects: 127
Study 1854617 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate clearance
Number of subjects: 127
Study 1854617 — intervention group
Group type: EXPERIMENTAL
Intervention: Low 6‐mercaptopurine (6‐MP) doses due to neutropaenia and higher doses of Mtx
Number of subjects: 127
Study 1854617 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance therapy in maximally tolerated doses
Number of subjects: 127
Study 6147940 — intervention group
Group type: EXPERIMENTAL
Intervention: beta 1‐blockade (100 mg metoprolol)
Number of subjects: 16
Study 6147940 — intervention group
Group type: EXPERIMENTAL
Intervention: beta 1/2‐blockade (2 mg levobunolol)
Number of subjects: 16
Study 30777651 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA (BoNT) prior to cognitive behavioral therapy (CBT)
Number of subjects: 14
Study 30777651 — intervention group
Group type: COMPARATOR
Intervention: Placebo prior to cognitive behavioral therapy (CBT)
Number of subjects: 14
Study 29402767 — intervention group
Group type: EXPERIMENTAL
Intervention: Bardoxolone methyl (20 mg once daily)
Number of subjects: 2185
Study 29402767 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2185
Study 26702121 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 IU daily oral vitamin D3 supplementation
Number of subjects: 75
Study 26702121 — intervention group
Group type: COMPARATOR
Intervention: 1000 IU daily oral vitamin D3 supplementation
Number of subjects: 75
Study 26702121 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 24915941 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (IFX)
Number of subjects: 20
Study 24915941 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab (ADA)
Number of subjects: 20
Study 22054213 — intervention group
Group type: EXPERIMENTAL
Intervention: Aneurysm clipping
Number of subjects: 500
Study 22054213 — intervention group
Group type: COMPARATOR
Intervention: Endovascular coil embolization
Number of subjects: 500
Study 21156112 — intervention group
Group type: EXPERIMENTAL
Intervention: Grøn Tuborg
Number of subjects: 57
Study 21156112 — intervention group
Group type: COMPARATOR
Intervention: Ceres Royal Pilsner
Number of subjects: 57
Study 18206031 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive patients
Number of subjects: 129
Study 18206031 — intervention group
Group type: COMPARATOR
Intervention: Normotensive patients
Number of subjects: 129
Study 15845315 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Cognitive Behavioral Therapy (CBT)
Number of subjects: 162
Study 15845315 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency Management (CM)
Number of subjects: 162
Study 15845315 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Cognitive Behavioral Therapy and Contingency Management (CBT+CM)
Number of subjects: 162
Study 15845315 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally Tailored Cognitive Behavioral Therapy (GCBT)
Number of subjects: 162
Study 15845315 — intervention group
Group type: COMPARATOR
Intervention: Overall (all treatments)
Number of subjects: 162
Study 12821551 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrophysiologically (EP)‐guided therapy
Number of subjects: 0
Study 12821551 — intervention group
Group type: COMPARATOR
Intervention: No EP‐guided therapy
Number of subjects: 0
Study 12821551 — intervention group
Group type: EXPERIMENTAL
Intervention: EP-guided therapy
Number of subjects: 0
Study 12821551 — intervention group
Group type: COMPARATOR
Intervention: No EP-guided therapy
Number of subjects: 0
Study 12821551 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD implantation
Number of subjects: 0
Study 12821551 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial EP-guided drug testing
Number of subjects: 0
Study 10382127 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloidal bismuth subcitrate (CBS) triple therapy
Number of subjects: 205
Study 10382127 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloidal bismuth pectin (CBP) triple therapy
Number of subjects: 205
Study 10382127 — intervention group
Group type: EXPERIMENTAL
Intervention: CBS quadruple therapy
Number of subjects: 205
Study 10382127 — intervention group
Group type: EXPERIMENTAL
Intervention: CBP quadruple therapy
Number of subjects: 205
Study 8916625 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral couples therapy (BCT)
Number of subjects: 80
Study 8916625 — intervention group
Group type: COMPARATOR
Intervention: No-couples-treatment control group
Number of subjects: 80
Study 1919540 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human interferon‐gamma (rIFN gamma) 0.1 mg/m2 intramuscularly thrice weekly for 16 weeks
Number of subjects: 19
Study 1919540 — intervention group
Group type: COMPARATOR
Intervention: no anti‐viral therapy (controls)
Number of subjects: 19
Study 6804900 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 36
Study 6804900 — intervention group
Group type: EXPERIMENTAL
Intervention: Norethisterone
Number of subjects: 36
Study 6804900 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 31033141 — intervention group
Group type: EXPERIMENTAL
Intervention: Wilms' tumor 1 peptide‐loaded dendritic cells (DCs) and OK‐432 adjuvant combined with conventional chemotherapy
Number of subjects: 11
Study 28872993 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I (complete removal of hypomineralized tissue)
Number of subjects: 126
Study 28872993 — intervention group
Group type: EXPERIMENTAL
Intervention: Group II (removal of carious and cheesy hypomineralized tissue)
Number of subjects: 126
Study 28872993 — intervention group
Group type: EXPERIMENTAL
Intervention: Group III (removal of hypomineralized tissue with deproteinization)
Number of subjects: 126
Study 28872993 — intervention group
Group type: COMPARATOR
Intervention: Group IV (control group, unaffected carious PFMs)
Number of subjects: 126
Study 25793967 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative health care (IHC) team collaboration during consensus case conferences
Number of subjects: 26
Study 25793967 — intervention group
Group type: EXPERIMENTAL
Intervention: Discourse analysis of IHC team interactions
Number of subjects: 26
Study 21712700 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirfenidone (PFD) 1800 mg/day for 6 months
Number of subjects: 34
Study 21712700 — intervention group
Group type: COMPARATOR
Intervention: Capsulectomy (control group)
Number of subjects: 34
Study 21187258 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional HF management guided by hemodynamic information from the CardioMEMS HF sensor
Number of subjects: 550
Study 21187258 — intervention group
Group type: COMPARATOR
Intervention: Traditional HF disease management
Number of subjects: 550
Study 19215685 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.03 mg/kg midazolam
Number of subjects: 45
Study 19215685 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 mg/kg midazolam
Number of subjects: 45